Mayukh Sukhatme, M.D. has served as chairman of our board of directors since July 2018. Since June 2018, Dr. Sukhatme has served as President of Roivant Pharma, a business unit of our controlling shareholder, RSL. Roivant Pharma is focused on end-to-end biopharmaceutical company creation, launch, and oversight. From November 2016 to June 2018, Dr. Sukhatme served as RSI’s Chief Business Officer and from April 2015 to November 2016 as Senior Vice President, Business Development. From 2000 to 2015, Dr. Sukhatme was a healthcare-focused analyst and portfolio manager for several large institutional investment firms, including both public markets and venture capital firms. His principal focus was on development-stage biotechnology and pharmaceutical companies, where he led diligence and investment decisions on numerous companies and pharmaceutical compounds across a wide variety of therapeutic areas. Dr. Sukhatme earned an M.D. from Harvard Medical School and a B.S. in Biology and a B.S. in Literature from the Massachusetts Institute of Technology.
Keith A. Katkin has served as our Principal Executive Officer since May 2018, a member of our board of directors since July 2018, and as the President and Chief Executive Officer of Urovant Sciences Inc. (USI) since September 2017. From March 2007 through January 2016, he was President and Chief Executive Officer of Avanir Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, where he led the company through its acquisition by Otsuka Pharmaceutical Co., Ltd. in 2015. He also served as a member of the board of directors of Avanir from 2007 to 2016. Mr. Katkin joined Avanir in July 2005 as the Senior Vice President of Sales and Marketing and a member of Avanir’s executive management team. From 2004 to 2005, Mr. Katkin served as the Vice President, Commercial Development for Peninsula Pharmaceuticals, Inc., a biopharmaceutical company, until it was acquired by Ortho-McNeil Pharmaceutical, Inc., a subsidiary of Johnson and Johnson. Additionally, Mr. Katkin’s employment experience includes leadership roles at InterMune, Inc., Amgen Inc. and Abbott Laboratories. Mr. Katkin currently serves as the chairman of the board of directors of Novus Therapeutics, Inc., and as a director of Syndax Pharmaceuticals Inc. and Rigel Pharmaceuticals, Inc., all of which are publicly traded biopharmaceutical companies. Mr. Katkin earned a B.S. in Business and Accounting from Indiana University and an M.B.A. from the Anderson School at University of California, Los Angeles.
Sef P. Kurstjens, M.D., Ph.D. has served as a member of our board of directors since July 2018. Dr Kurstjens most recently served as Chief Medical Officer at Astellas from April 2013 to April 2018. At Astellas, Dr. Kurstjens was responsible for development, regulatory affairs, medical affairs, pharmacovigilance and quality assurance and was a member of the Corporate Executive Committee. From 2010 to 2013, Dr. Kurstjens was the President and Chief Executive Officer at Agensys, Inc., an early stage oncology Astellas affiliate. Previously, from 2007 to 2010, Dr. Kurstjens served as the Senior Vice President, Chief Medical Officer and Head, Global Drug Development at Allergan. Dr. Kurstjens entered the pharmaceutical industry with Sandoz Pharmaceuticals (now a Novartis International AG company) in Basel, Switzerland in 1991, and from 1993 to 2005 held positions of increasing responsibility with Pfizer Inc. in both Europe and the United States, including VP Worldwide Therapeutic Area Head of Gastrointestinal and Genitourinary. Dr. Kurstjens received his qualifications in medicine and physiology from University of the Witwatersrand in Johannesburg, South Africa.
Pierre Legault has served as a member of our board of directors since July 2018. Mr. Legault has served on the board of directors of Poxel SA since January 2016 and has been Chairman of the board since March 2016. Since February 2018, Mr. Legault has also served on the board of directors and as Chairman of the board for Artios Pharma Limited. Mr. Legault is also a director of Clementia Pharmaceuticals Inc. and Syndax Pharmaceuticals Inc. since January 2018 and January 2017, respectively. Mr. Legault has also previously served as a member of the boards of directors at Forest Laboratories, Tobira Therapeutics, Inc., NPS Pharmaceuticals, Inc., Regado Biosciences, Inc., ARMO Biosciences, Iroko Pharmaceuticals LLC, Cyclacel Pharmaceuticals Inc., Eckerd Pharmacy and NephroGenex, Inc., where he also served as the Chairman and Chief Executive Officer from 2012 to 2016. From 2010 to 2012, Mr. Legault served as the Chief Executive Officer of Prosidion Ltd., a subsidiary of Astellas, and from 2009 to 2010, he served as the Chief Financial Officer and Treasurer of OSI Pharmaceuticals, Inc. Mr. Legault also previously served as the Chief Executive Officer of Eckerd Pharmacy and Senior Executive Vice President and Chief Accounting Officer of the Rite Aid Corporation. Between 1989 and 2005, Mr. Legault held various global roles such as President, Chief Executive Officer and Chief Financial Officer at legacy companies of the Sanofi group. Mr. Legault earned a B.B.A. in Business & International Finance from HEC Montreal, an M.B.A. in Marketing from McGill University and holds C.A. and C.P.A. diplomas. He also studied at Harvard Business School in its Graduate Executive MBA program.
Matthew Gline has served as a member of our board of directors since July 2018. Since September 2017, Mr. Gline has also served as the Chief Financial Officer of Roivant Sciences, Inc., or RSI. Mr. Gline previously served as RSI’s Senior Vice President, Finance and Business Operations since March 2016. From April 2014 to March 2016, he was a Vice President, Fixed Income Digital Structuring, at Goldman Sachs, where he focused on technology and data strategy. Prior to Goldman Sachs, Mr. Gline was a co-founder of Fourthree, Inc., a risk analytics technology and consulting company. From 2008 to 2012, he served as Vice President, Enterprise Risk Management Advisory, at Barclays Investment Bank, where he provided analysis for corporate clients related to capital markets access for financing and risk management. Mr. Gline earned a B.A. in Physics from Harvard University.